Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | FCER2 | P06734 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27382220 | 0.91 | OPRD1 (0.51) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL25773989 | 0.90 | CTSS (0.52) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL18477610 | 0.89 | CTSS (0.49) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL20880680 | 0.89 | CTSS (0.53) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL27361383 | 0.88 | OPRD1 (0.49) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL24380508 | 0.88 | OPRD1 (0.53) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL18513842 | 0.88 | CTSS (0.54) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL26575093 | 0.87 | CTSS (0.47) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL25976737 | 0.86 | CTSS (0.55) | CTSSCTSLCTSBOPRD1OPRM1 | |
| SCHEMBL26512014 | 0.85 | CTSS (0.46) | CTSSCTSLCTSBOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | CTSS 1937/4885CTSL 1206/4885CTSB 1659/4885 |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | CTSS 1937/4885CTSL 1206/4885CTSB 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.